Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes-Reference-Cited by-同舟云学术

Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes

Published:2020-01-20 Issue:2 Volume:80 Page:147-165
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Harris Stewart^ORCID,Abrahamson Martin J.,Ceriello Antonio^ORCID,Charpentier Guillaume^ORCID,Evans Marc,Lehmann Roger^ORCID,Liebl Andreas^ORCID,Linjawi Sultan^ORCID,Holt Richard I. G.^ORCID,Hosszúfalusi Nóra^ORCID,Rutten Guy^ORCID,Vilsbøll Tina^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40265-019-01245-3.pdf

Reference95 articles.

1. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia. 2003;46(1):3–19.

2. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes 2018. Diabetes Care. 2019;42(Suppl 1):S90–102.

3. Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–701.

4. Nuffer W, Guesnier A, Trujillo JM. A review of the new GLP-1 receptor agonist/basal insulin fixed-ratio combination products. Ther Adv Endocrinol Metab. 2018;9(3):69–79.

5. Anderson SL, Trujillo JM. Basal insulin use with GLP-1 receptor agonists. Diabetes Spectr. 2016;29(3):152–60.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness, Simplification and Persistence of IDegLira in Poorly Controlled People with Type 2 Diabetes: A 4-Year Follow-Up Real-World Study;Diabetes Therapy;2024-04-11

2. Immediate Impact of Switching from Dipeptidyl Peptidase 4 (DPP4) Inhibitors to Low-Dose (0.3 mg) Liraglutide on Glucose Profiles: A Retrospective Observational Study;Diabetes Therapy;2024-03-18

3. Construction and Identification of a Breast Bioreactor for Human-Derived Hypoglycemic Protein Amylin;Life;2024-01-28

4. Simplification of Complex Insulin Regimens with IdegLira in People with Type 2 Diabetes: Literature Review and Clinical Recommendations;Diabetes Therapy;2023-09-22

5. Retrospective Study of IDegLira, a New Fixed-Ratio Combination, in Japanese Patients With Type 2 Diabetes Mellitus: Analysis of Background Factors Affecting Effectiveness After 6 Months of Treatment;Journal of Clinical Medicine Research;2023-09